glp-1 compounding crackdown news october 2025 The FDA announced plans to take action against non-FDA-approved receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded semaglutide (Wegovy) weight-loss pill from the Despite FDA crackdown, unapproved GLP-1s
Description
Men were slightly more likely than women to experience this effect (77% compared to 72%, respectively)
The lawsuits also assert that the companies did not sufficiently inform users about the risk of conditions like gastroparesis, cyclic vomiting syndrome, and bowel obstruction
Arakawa M, Ebato C, Mita T, Hirose T, Kawamori R, Fujitani Y, et al
We pair dosing with protein forward nutrition and consistent strength training so the body maintains or builds lean tissue while gently encouraging fat loss
Email us
it relies on a temporary demonstration authority instead, and its future past 2027 is genuinely uncertain
